表紙
市場調查報告書

腎盂腎炎:開發中產品分析

Pyelonephritis - Pipeline Review, H2 2019

出版商 Global Markets Direct 商品編碼 251523
出版日期 內容資訊 英文 122 Pages
訂單完成後即時交付
價格
Back to Top
腎盂腎炎:開發中產品分析 Pyelonephritis - Pipeline Review, H2 2019
出版日期: 2019年11月25日內容資訊: 英文 122 Pages
簡介

所謂腎盂腎炎是特殊的一種泌尿道感染(UTI),通常從尿道和膀胱發病再轉到腎臟。主要的症狀·前兆有發熱和腹痛,頻繁的排尿,噁心嘔吐,意識混濁,背部痛·側腹部痛等。主要的致病因子包含了免疫系的弱化,及膀胱週邊神經的損傷等。主要的治療方法有抗生素等。

本報告提供全球各國的腎盂腎炎治療用的開發中產品的開發情形相關分析,提供您開發中產品的最新趨勢,及臨床實驗的各階段產品一覽,主要企業簡介,主要藥物概要,最新的產業趨勢等調查結果。

目錄

簡介

  • 分析範圍

腎盂腎炎概要

治療藥的開發

  • 腎盂腎炎開發中產品:概要
  • 企業開發中的治療藥
  • 企業開發中的產品

治療藥的評估

  • 標的別
  • 各作用機制
  • 各給藥途徑
  • 各分子類型

開發治療藥的企業

  • Achaogen Inc.
  • AstraZeneca Plc
  • Merck & Co., Inc.
  • MerLion Pharmaceuticals Pte Ltd
  • The Medicines Company
  • Zavante Therapeutics Inc

藥物簡介

暫停中的計劃

開發中止的產品

產品開發的里程碑

  • 主要消息和新聞稿

附錄

圖表一覽

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC11547IDB

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Pyelonephritis - Pipeline Review, H2 2019, provides an overview of the Pyelonephritis (Infectious Disease) pipeline landscape.

Pyelonephritis is a specific type of urinary tract infection (UTI) that generally begins in urethra or bladder and travels up into kidneys. Signs and symptoms include fever, abdominal pain, frequent urination, nausea and vomiting, confusion and back pain or flank pain. Predisposing factors include weakened immune system, obstruction in the urinary tract and damage to nerves around the bladder. Treatment includes antibiotics.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Pyelonephritis - Pipeline Review, H2 2019, provides comprehensive information on the therapeutics under development for Pyelonephritis (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Pyelonephritis (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Pyelonephritis and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Filing rejected/Withdrawn, Phase III, Phase II, Phase I and Preclinical stages are 1, 1, 5, 6, 1 and 2 respectively.

Pyelonephritis (Infectious Disease) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Pyelonephritis (Infectious Disease).
  • The pipeline guide reviews pipeline therapeutics for Pyelonephritis (Infectious Disease) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Pyelonephritis (Infectious Disease) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Pyelonephritis (Infectious Disease) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Pyelonephritis (Infectious Disease)

Reasons to buy

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Pyelonephritis (Infectious Disease).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Pyelonephritis (Infectious Disease) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

  • List of Tables
  • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Pyelonephritis - Overview
  • Pyelonephritis - Therapeutics Development
    • Pipeline Overview
    • Pipeline by Companies
    • Products under Development by Companies
  • Pyelonephritis - Therapeutics Assessment
    • Assessment by Target
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Pyelonephritis - Companies Involved in Therapeutics Development
    • Achaogen Inc
    • Allecra Therapeutics GmbH
    • AlloVir Inc
    • Entasis Therapeutics Inc
    • Iterum Therapeutics Plc
    • Jiangsu Sinoyoung Bio-Pharmaceutical Co Ltd
    • Meiji Seika Pharma Co Ltd
    • Melinta Therapeutics Inc
    • Merck & Co Inc
    • MerLion Pharmaceuticals Pte Ltd
    • Nabriva Therapeutics Plc
    • Paratek Pharmaceuticals Inc
    • VenatoRx Pharmaceuticals Inc
    • Wockhardt Ltd
    • XuanZhu Pharma Co Ltd
  • Pyelonephritis - Drug Profiles
    • (AAI-101 + cefepime) - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • (cefepime + tazobactam sodium) - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • (cefepime + VNRX-5133) - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • (ceftolozane sulfate + tazobactam sodium) - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • (durlobactam sodium + sulbactam) - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • (meropenem + vaborbactam) - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • ALVR-105 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • benapenem - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • ceforanide - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • finafloxacin - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • fosfomycin disodium - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • nacubactam - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • omadacycline tosylate - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • plazomicin sulfate - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • sulopenem - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • tebipenem pivoxil hydrobromide - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
  • Pyelonephritis - Dormant Projects
  • Pyelonephritis - Discontinued Products
  • Pyelonephritis - Product Development Milestones
    • Featured News & Press Releases
      • Sep 03, 2019: Allecra Therapeutics to present data at ASM/ESCMID 2019 Conference on drug development to meet the challenge of antimicrobial resistance
      • Jul 29, 2019: Merck receives positive EU CHMP opinion for ZERBAXA 3g dose (ceftolozane and tazobactam) for the treatment of adults with Hospital-Acquired Pneumonia (HAP), Including Ventilator-Associated Pneumonia (VAP)
      • Apr 15, 2019: Paratek Pharmaceuticals broadens clinical profile of NUZYRA (Omadacycline) with New ECCMID 2019 Data Presentations
      • Apr 10, 2019: Entasis Therapeutics announces presentations on ETX2514SUL at ECCMID 2019
      • Mar 29, 2019: Spero Therapeutics receives FDA fast track designation for SPR994 for the treatment of complicated urinary tract infections and acute pyelonephritis
      • Feb 21, 2019: Achaogen announces ZEMDRI (plazomicin) pivotal phase 3 study results published in the New England Journal of Medicine
      • Feb 14, 2019: Achaogen submits response to ASPR/BARDA request for information (RFI) for antimicrobial resistance project BioShield
      • Dec 11, 2018: The Menarini Group announces Meropenem/vaborbactam European marketing authorization
      • Nov 27, 2018: Paratek Pharmaceuticals doses first patient in phase 2 clinical trial of Omadacycline in acute pyelonephritis, a common subset of complicated urinary tract infections
      • Oct 17, 2018: Achaogen submits marketing authorization application to the European Medicines Agency for Plazomicin
      • Oct 03, 2018: Entasis Therapeutics to Present on ETX2514SUL at IDWeek 2018
      • Sep 19, 2018: Achaogen announces multiple Plazomicin presentations at IDWeek 2018
      • Sep 04, 2018: Achaogen highlights multiple Plazomicin presentations at ESCMID/ASM 2018 Conference
      • Aug 14, 2018: Entasis Therapeutics announces positive topline results from phase 2 trial of ETX2514SUL in patients with complicated urinary tract infections including acute pyelonephritis
      • Aug 03, 2018: CMS grants new technology add-on payment to ZEMDRI (plazomicin)
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Table 1: Number of Products under Development for Pyelonephritis, H2 2019
  • Table 2: Number of Products under Development by Companies, H2 2019
  • Table 3: Products under Development by Companies, H2 2019
  • Table 4: Number of Products by Stage and Target, H2 2019
  • Table 5: Number of Products by Stage and Mechanism of Action, H2 2019
  • Table 6: Number of Products by Stage and Route of Administration, H2 2019
  • Table 7: Number of Products by Stage and Molecule Type, H2 2019
  • Table 8: Pyelonephritis - Pipeline by Achaogen Inc, H2 2019
  • Table 9: Pyelonephritis - Pipeline by Allecra Therapeutics GmbH, H2 2019
  • Table 10: Pyelonephritis - Pipeline by AlloVir Inc, H2 2019
  • Table 11: Pyelonephritis - Pipeline by Entasis Therapeutics Inc, H2 2019
  • Table 12: Pyelonephritis - Pipeline by Iterum Therapeutics Plc, H2 2019
  • Table 13: Pyelonephritis - Pipeline by Jiangsu Sinoyoung Bio-Pharmaceutical Co Ltd, H2 2019
  • Table 14: Pyelonephritis - Pipeline by Meiji Seika Pharma Co Ltd, H2 2019
  • Table 15: Pyelonephritis - Pipeline by Melinta Therapeutics Inc, H2 2019
  • Table 16: Pyelonephritis - Pipeline by Merck & Co Inc, H2 2019
  • Table 17: Pyelonephritis - Pipeline by MerLion Pharmaceuticals Pte Ltd, H2 2019
  • Table 18: Pyelonephritis - Pipeline by Nabriva Therapeutics Plc, H2 2019
  • Table 19: Pyelonephritis - Pipeline by Paratek Pharmaceuticals Inc, H2 2019
  • Table 20: Pyelonephritis - Pipeline by VenatoRx Pharmaceuticals Inc, H2 2019
  • Table 21: Pyelonephritis - Pipeline by Wockhardt Ltd, H2 2019
  • Table 22: Pyelonephritis - Pipeline by XuanZhu Pharma Co Ltd, H2 2019
  • Table 23: Pyelonephritis - Dormant Projects, H2 2019
  • Table 24: Pyelonephritis - Discontinued Products, H2 2019

List of Figures

  • Figure 1: Number of Products under Development for Pyelonephritis, H2 2019
  • Figure 2: Number of Products under Development by Companies, H2 2019
  • Figure 3: Number of Products by Top 10 Targets, H2 2019
  • Figure 4: Number of Products by Stage and Top 10 Targets, H2 2019
  • Figure 5: Number of Products by Top 10 Mechanism of Actions, H2 2019
  • Figure 6: Number of Products by Stage and Top 10 Mechanism of Actions, H2 2019
  • Figure 7: Number of Products by Routes of Administration, H2 2019
  • Figure 8: Number of Products by Stage and Top 10 Routes of Administration, H2 2019
  • Figure 9: Number of Products by Molecule Types, H2 2019
  • Figure 10: Number of Products by Stage and Top 10 Molecule Types, H2 2019
Back to Top